Income Statement
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Abbott Laboratories, consolidated income statement (quarterly data)

US$ in millions

3 months ended:	Jun 30, 2026	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021
Net sales	12,593)	11,164)	11,459)	11,369)	11,142)	10,358)	10,974)	10,635)	10,377)	9,964)	10,241)	10,143)	9,978)	9,747)	10,091)	10,410)	11,257)	11,895)	11,468)	10,928)	10,223)	10,456)
Cost of products sold, excluding amortization of intangible assets	(5,325)	(4,890)	(4,922)	(5,075)	(4,854)	(4,468)	(4,942)	(4,698)	(4,603)	(4,463)	(4,556)	(4,605)	(4,483)	(4,331)	(4,593)	(4,629)	(4,933)	(4,987)	(4,766)	(4,423)	(4,947)	(4,401)
Amortization of intangible assets	(658)	(422)	(422)	(420)	(420)	(420)	(465)	(470)	(471)	(472)	(481)	(496)	(498)	(491)	(496)	(498)	(507)	(512)	(514)	(520)	(504)	(509)
Gross profit	6,610)	5,852)	6,115)	5,874)	5,868)	5,470)	5,567)	5,467)	5,303)	5,029)	5,204)	5,042)	4,997)	4,925)	5,002)	5,283)	5,817)	6,396)	6,188)	5,985)	4,772)	5,546)
Research and development	(892)	(767)	(735)	(766)	(725)	(716)	(749)	(713)	(698)	(684)	(700)	(672)	(715)	(654)	(725)	(782)	(684)	(697)	(762)	(672)	(654)	(654)
Selling, general and administrative	(4,025)	(3,740)	(3,129)	(3,051)	(3,091)	(3,061)	(2,907)	(2,895)	(2,936)	(2,959)	(2,724)	(2,723)	(2,740)	(2,762)	(2,973)	(2,731)	(2,757)	(2,787)	(3,048)	(2,767)	(2,726)	(2,783)
Operating earnings	1,693)	1,345)	2,251)	2,057)	2,052)	1,693)	1,911)	1,859)	1,669)	1,386)	1,780)	1,647)	1,542)	1,509)	1,304)	1,770)	2,376)	2,912)	2,378)	2,546)	1,392)	2,109)
Interest expense	(351)	(174)	(120)	(121)	(121)	(131)	(136)	(142)	(140)	(141)	(159)	(166)	(159)	(153)	(154)	(141)	(132)	(131)	(131)	(133)	(134)	(135)
Interest income	52)	106)	78)	77)	71)	82)	91)	91)	82)	80)	89)	97)	98)	101)	88)	55)	26)	14)	11)	10)	11)	11)
Net foreign exchange gain (loss)	(4)	13)	15)	17)	11)	7)	10)	11)	6)	—)	(24)	10)	(21)	(6)	14)	(19)	—)	3)	6)	(4)	—)	(3)
Other income (expense), net	134)	159)	134)	150)	137)	127)	154)	121)	(10)	111)	109)	83)	176)	111)	68)	93)	82)	78)	63)	74)	79)	61)
Earnings before taxes	1,524)	1,449)	2,358)	2,180)	2,150)	1,778)	2,030)	1,940)	1,607)	1,436)	1,795)	1,671)	1,636)	1,562)	1,320)	1,758)	2,352)	2,876)	2,327)	2,493)	1,348)	2,043)
Taxes on earnings	(596)	(372)	(582)	(536)	(371)	(453)	7,199)	(294)	(305)	(211)	(201)	(235)	(261)	(244)	(287)	(323)	(334)	(429)	(338)	(393)	(159)	(250)
Net earnings	928)	1,077)	1,776)	1,644)	1,779)	1,325)	9,229)	1,646)	1,302)	1,225)	1,594)	1,436)	1,375)	1,318)	1,033)	1,435)	2,018)	2,447)	1,989)	2,100)	1,189)	1,793)

Revenue performance exhibits a cyclical pattern over the observed period. Net sales peaked in the first quarter of 2022 at 11,895 million US dollars before entering a period of contraction that bottomed out in the first quarter of 2023 at 9,747 million US dollars. A sustained recovery followed, with sales trending upward to reach a period high of 12,593 million US dollars by June 30, 2026.

Gross Profitability and Margin Trends: Gross profit generally tracks with net sales, although margins have fluctuated. The gross profit margin remained relatively resilient, though a notable compression occurred between late 2022 and early 2023. By the second quarter of 2026, gross profit reached 6,610 million US dollars, indicating an improved ability to manage direct product costs relative to the sales recovery.
Operating Expense Analysis: Research and development expenses remained remarkably stable for several years, typically fluctuating between 650 million and 760 million US dollars, before increasing to 892 million US dollars in June 2026. Selling, general, and administrative expenses showed a more pronounced upward trajectory in the most recent periods. After remaining steady near 2.7 billion to 3.1 billion US dollars for several years, these expenses surged to 3.74 billion US dollars in March 2026 and 4.025 billion US dollars in June 2026, significantly impacting operating earnings.
Operating and Net Earnings Volatility: Operating earnings peaked in early 2022 at 2,912 million US dollars, followed by a decline that reached a low of 1,304 million US dollars in December 2022. While earnings recovered through 2024 and 2025, the sharp increase in operating expenses in early 2026 led to a contraction in operating earnings, which fell to 1,693 million US dollars by June 2026.
Non-Operating Items and Tax Anomalies: A significant anomaly is observed in the fourth quarter of 2024, where net earnings spiked to 9,229 million US dollars. This was driven by a positive tax entry of 7,199 million US dollars, suggesting a one-time tax benefit or accounting adjustment rather than operational growth. Interest expenses remained stable around 130-160 million US dollars for most of the period but saw a sharp increase to 351 million US dollars in June 2026.
Net Income Trajectory: Excluding the atypical tax event of late 2024, net earnings show a pattern of volatility. After a period of growth peaking in early 2022, net earnings declined through 2023. While there was a recovery in 2025, the trend reversed in the first half of 2026, with net earnings dropping to 928 million US dollars in June 2026, primarily due to the simultaneous rise in SG&A and interest expenses.

AI Ask an analyst for more

Download chart

Abbott Laboratories (NYSE:ABT)

Income StatementQuarterly Data

Income Statement
Quarterly Data